These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 32724829

  • 1. Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials.
    Yang J, Wang Z, Zhang X.
    J Immunol Res; 2020; 2020():4975628. PubMed ID: 32724829
    [Abstract] [Full Text] [Related]

  • 2. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
    Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA.
    Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277
    [Abstract] [Full Text] [Related]

  • 3. Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.
    Puig L, Wu JJ, Gooderham MJ, You Y, Shen YK, Randazzo B, Kerdel F.
    J Dermatolog Treat; 2021 Aug; 32(5):484-491. PubMed ID: 31613178
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis: post-hoc analysis from the phase III, double-blind, placebo- and active-comparator-controlled VOYAGE 1/2 trials.
    Youn SW, Yu DY, Kim TY, Kim BS, Lee SC, Lee JH, Choe YB, Lee JH, Choi JH, Roh JY, Jo SJ, Lee ES, Shin MK, Lee MG, Jiang J, Lee Y.
    J Dermatolog Treat; 2022 Feb; 33(1):535-541. PubMed ID: 32419536
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
    Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.
    JAMA Dermatol; 2018 Jun 01; 154(6):676-683. PubMed ID: 29799960
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB.
    J Am Acad Dermatol; 2017 Mar 01; 76(3):405-417. PubMed ID: 28057360
    [Abstract] [Full Text] [Related]

  • 8. Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis.
    Teeple A, Muser E.
    J Med Econ; 2019 Dec 01; 22(12):1268-1273. PubMed ID: 31199173
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of guselkumab compared with adalimumab for psoriasis: a meta-analysis of randomized controlled studies.
    Fu H, Guo J.
    Postepy Dermatol Alergol; 2022 Oct 01; 39(5):953-958. PubMed ID: 36457680
    [Abstract] [Full Text] [Related]

  • 10. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
    Reich K, Griffiths CEM, Gordon KB, Papp KA, Song M, Randazzo B, Li S, Shen YK, Han C, Kimball AB, Armstrong AW, Foley P, Blauvelt A.
    J Am Acad Dermatol; 2020 Apr 01; 82(4):936-945. PubMed ID: 31809827
    [Abstract] [Full Text] [Related]

  • 11. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J, IXORA-R Study Group.
    Br J Dermatol; 2020 Jun 01; 182(6):1348-1358. PubMed ID: 31887225
    [Abstract] [Full Text] [Related]

  • 12. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
    Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, You Y, Shen YK, Reich K.
    J Eur Acad Dermatol Venereol; 2018 Nov 01; 32(11):1940-1949. PubMed ID: 29706008
    [Abstract] [Full Text] [Related]

  • 13. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
    Ohtsuki M, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H.
    J Dermatol; 2018 Sep 01; 45(9):1053-1062. PubMed ID: 29905383
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab.
    Reich K, Foley P, Han C, McElligott S, Muser E, Li N, Armstrong AW.
    J Dermatolog Treat; 2020 Sep 01; 31(6):617-623. PubMed ID: 31305186
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis.
    Xue W, Saharia P, Gray E, Khoudigian-Sinani S, Gaudet V, Barbeau M, Papp K.
    J Cutan Med Surg; 2020 Sep 01; 24(6):561-572. PubMed ID: 32588642
    [Abstract] [Full Text] [Related]

  • 17. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K.
    N Engl J Med; 2015 Jul 09; 373(2):136-44. PubMed ID: 26154787
    [Abstract] [Full Text] [Related]

  • 18. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A.
    Lancet; 2019 Sep 07; 394(10201):831-839. PubMed ID: 31402114
    [Abstract] [Full Text] [Related]

  • 19. Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis.
    Xu S, Zhang X, Pan M, Shuai Z, Xu S, Pan F.
    Int Immunopharmacol; 2019 Oct 07; 75():105841. PubMed ID: 31465912
    [Abstract] [Full Text] [Related]

  • 20. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
    Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, You Y, Han C, Yang YW, Foley P, Griffiths CEM.
    Br J Dermatol; 2021 Dec 07; 185(6):1146-1159. PubMed ID: 34105767
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.